DE1910986A1 - Analgetica - Google Patents
AnalgeticaInfo
- Publication number
- DE1910986A1 DE1910986A1 DE19691910986 DE1910986A DE1910986A1 DE 1910986 A1 DE1910986 A1 DE 1910986A1 DE 19691910986 DE19691910986 DE 19691910986 DE 1910986 A DE1910986 A DE 1910986A DE 1910986 A1 DE1910986 A1 DE 1910986A1
- Authority
- DE
- Germany
- Prior art keywords
- substance
- pharmaceutically acceptable
- amount
- propoxyphene
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000730 antalgic agent Substances 0.000 title claims 2
- 229940035676 analgesics Drugs 0.000 title 1
- 239000000126 substance Substances 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 16
- 229960004193 dextropropoxyphene Drugs 0.000 claims description 13
- 230000000202 analgesic effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 claims 1
- UCEXMJMSILZCHZ-UHFFFAOYSA-N 2-[(4-butoxybenzoyl)amino]acetic acid Chemical compound CCCCOC1=CC=C(C(=O)NCC(O)=O)C=C1 UCEXMJMSILZCHZ-UHFFFAOYSA-N 0.000 claims 1
- 241000711981 Sais Species 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 229940065347 propoxyphene hydrochloride Drugs 0.000 claims 1
- 235000008001 rakum palm Nutrition 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 229960003529 diazepam Drugs 0.000 description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000002936 tranquilizing effect Effects 0.000 description 5
- 208000010428 Muscle Weakness Diseases 0.000 description 4
- 206010028372 Muscular weakness Diseases 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000003204 tranquilizing agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 229940125725 tranquilizer Drugs 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- -1 moleates Chemical class 0.000 description 2
- HQTOGRJJEXEVDY-UHFFFAOYSA-N 2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine;hydrochloride Chemical compound Cl.CCCOC1=C(OC)C=C(CCN)C=C1OC HQTOGRJJEXEVDY-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 241000252185 Cobitidae Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical group C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70986768A | 1968-03-04 | 1968-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1910986A1 true DE1910986A1 (de) | 1969-09-25 |
Family
ID=24851606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691910986 Pending DE1910986A1 (de) | 1968-03-04 | 1969-03-04 | Analgetica |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS4910725B1 (enExample) |
| BE (1) | BE729239A (enExample) |
| CA (1) | CA974882A (enExample) |
| DE (1) | DE1910986A1 (enExample) |
| FR (1) | FR2003193A1 (enExample) |
| GB (1) | GB1261454A (enExample) |
| IL (1) | IL31722A (enExample) |
| NL (1) | NL6903352A (enExample) |
| SE (1) | SE368774B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5752813U (enExample) * | 1980-09-11 | 1982-03-26 | ||
| FR2522145A1 (fr) * | 1982-02-23 | 1983-08-26 | Floc H Joseph | Capteur de pression et/ou de depression pneumatique du type a balance de forces, pour application avec des fluides agressifs ou inertes |
-
1969
- 1969-02-27 CA CA044,139A patent/CA974882A/en not_active Expired
- 1969-03-02 IL IL31722A patent/IL31722A/xx unknown
- 1969-03-03 BE BE729239D patent/BE729239A/xx unknown
- 1969-03-04 GB GB01544/69A patent/GB1261454A/en not_active Expired
- 1969-03-04 FR FR6905837A patent/FR2003193A1/fr not_active Withdrawn
- 1969-03-04 JP JP44016415A patent/JPS4910725B1/ja active Pending
- 1969-03-04 NL NL6903352A patent/NL6903352A/xx unknown
- 1969-03-04 DE DE19691910986 patent/DE1910986A1/de active Pending
- 1969-03-04 SE SE02986/69A patent/SE368774B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL31722A (en) | 1972-10-29 |
| CA974882A (en) | 1975-09-23 |
| NL6903352A (enExample) | 1969-09-08 |
| SE368774B (enExample) | 1974-07-22 |
| JPS4910725B1 (enExample) | 1974-03-12 |
| IL31722A0 (en) | 1969-05-28 |
| GB1261454A (en) | 1972-01-26 |
| FR2003193A1 (fr) | 1969-11-07 |
| BE729239A (enExample) | 1969-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69034149T2 (de) | Verwendung von Sertralin zur Behandlung von posttraumatischen Stresserkrankungen | |
| DE2813480C2 (de) | Arzneimittel-Depotpräparat vom Mehrfacheinheitsdosen-Typ | |
| EP0138018A2 (de) | Lösungen milchsaurer Salze von Piperazinylchinolon- und Piperazinyl-azachinoloncarbonsäuren | |
| DE60122015T2 (de) | Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz | |
| DE10334820B4 (de) | Pharmazeutische Zusammensetzungen mit antibiotischer Aktivität | |
| DE69333413T2 (de) | 5-ht2-antagonisten in der behandlung venöser zustände | |
| EP0214620A2 (de) | Transdermale Applikationsform von Diltiazem | |
| DE2608079C2 (de) | Arzneipräparate in Form eines Trockenpräparates in Pulverform zur Herstellung von Injektionen durch Zugabe eines wäßrigen Verdünnungsmittels | |
| DE1910986A1 (de) | Analgetica | |
| CH647677A5 (de) | 4'-(acridinylamino)-methansulfon-anisidid enthaltende pharmazeutische zusammensetzung. | |
| DE69004529T2 (de) | Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen. | |
| DE3852717T2 (de) | Zusammensetzung für die Prophylaxe von Pneumocystis-carinii-Pneumonie. | |
| DE10163667A1 (de) | Verwendung von Desoxypeganin zur Behandlung der klinischen Depression | |
| CH649918A5 (de) | Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie. | |
| DE2314387C3 (de) | Arzneimittel zur Behandlung bösartiger Neubildungen | |
| DE1923772C3 (de) | Oral oder parenteral verabreichbare Arzneimittel mit ulkushemmender Wirkung | |
| DE102004031538A1 (de) | Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit | |
| EP0005732A1 (de) | Verwendung von 2-Amino-oxazolo- oder 2-Amino-thiazolo-[5,4-d]azepinen sowie deren Säureadditionssalzen zur Herstellung eines Arzneimittels für die Verwendung bei der Bekämpfung von Angina Pectoris | |
| DE3003147A1 (de) | Suppositorium mit einem gehalt an sulfamethoxazol und trimethoprim | |
| DE2356369C2 (de) | Pharmazeutisches Präparat, enthaltend eine oder mehrere Benzodiazepinverbindungen | |
| DE2422612C3 (de) | .Verwendung von 2,6-trans-Diphenylhexamethylcyclotetrasiloxan zur Herstellung eines oral oder intravenös verabreichbaren Arzneimittels zur Erhöhung des Dopamingehalts fan Gehirn von Tieren | |
| DE4244265A1 (de) | Ausbildung von neuen spezifischen Bindungsstellen für Paf und seine Analoge sowie Paf-Antagonisten auf endothelialen Zellen | |
| DE2636328A1 (de) | Arzneimittel | |
| DE3129714A1 (de) | Anti-psychotikum | |
| DE1804634A1 (de) | Neue pharmazeutische Zusammensetzung |